Sanofi entered into a definitive agreement to acquire ownership of Qunol, subject to customary closing conditions, including applicable regulatory approvals. The acquisition is expected to close Q3 2023.
Sanofi officials said this transaction will strengthen Sanofi’s Consumer Healthcare’s vitamin, mineral and supplements category, one of the largest and fastest-growing consumer health categories in the U.S., with a focus on the active ‘healthy aging’ segment.
With Qunol’s CoQ10 in heart health and Turmeric in joint health, CHC at Sanofi adds a trusted, profitable double-digit growth brand to its U.S. portfolio, focused on chronic conditions with growing consumer demand. With this acquisition, Sanofi continues to pursue growth opportunities and value creation for its consumer healthcare business.
Julie Van Ongevalle, EVP consumer healthcare at Sanofi, said the acquisition strengthens Sanofi’s overall profile.
“It taps into the growing ‘healthy aging’ segment and fills one of our white spaces in the U.S., unlocking an opportunity for us to build on our U.S. presence and accelerate our growth,” she said. “VMS now functions as long-term support for overall health and wellness where proactive preventive health has become the new norm post-pandemic.
Qunol CoQ10 and Turmeric products are both backed by science literature and strong market positioning in their segments. Qunol’s high product quality and efficacy have resulted in strong brand equity among consumers and customers, as well as above category consumer loyalty. The Qunol brand will benefit from Sanofi’s CHC resources to expand into other chronic conditions and develop its footprint outside the U.S.
Peter Boutros, CEO of Quten Research Institute, said the acquisition will be good for the company.
“With Sanofi, we have the opportunity to further grow in the U.S. and beyond, tapping into Sanofi Consumer Healthcare’s commercial breadth and strength,” he said.